Jade Biosciences Inc (JBIO)

$7.70 -0.06 (-0.77%)
Market Cap 251.23M
Revenue (ttm) 0.00
Net Income (ttm) -69.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 37,900
Avg Vol 119,656
Day's Range N/A - N/A
Shares Out 32.63M
Stochastic %K 56%
Beta 1.04
Analysts Strong Sell
Price Target $16.75

Company Profile

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company was incorporated in 2024 and is headquartered in Waltham, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 916 322 1700
Address:
221 Crescent Street Building 23, Suite 105, Waltham, United States
dogDazeSummer
dogDazeSummer Sep. 9 at 2:43 PM
Only 5 new adds for RA in latest Q: $HNGE $JBIO $TNGX $WGS and a “pipeline in pill” company from Germany, forgot the name. Total holdings are 63 many making ATH today. Interesting focus on immune dermatology. Here’s how much cash he dropped into each new starter position: Might want to follow these 5 names. $15M into Hinge $9.9m into Jade $7.3m into Omada $5.4m into GeneDx $3.2k into Inflarx
1 · Reply
GrowthStrategist
GrowthStrategist Aug. 27 at 10:17 AM
$JBIO hovering near recent highs, careful of a pullback.
0 · Reply
JarvisFlow
JarvisFlow Aug. 14 at 2:03 PM
Wedbush has updated their rating for Jade Biosciences ( $JBIO ) to Outperform with a price target of 18.
0 · Reply
Quantumup
Quantumup Jul. 14 at 7:09 PM
Jefferies🏁 $JBIO Buy-$16 $VRTX $OTSKF Jefferies said in its initiation report: "We like $JBIO's long-acting anti-APRIL (JADE101) in IgAN: 1) our PK work suggests '101 can achieve Q8/12W dosing, 2) we think efficacy will be as good as povetacicept w/ pot'l upside on % clinical remission, 3) we expect tolerable safety profile w/o increased serious infections, 4) we see oppty for disease modifying tx w/ longer dosing interval in IgAN. We model $915M risk-adj. PS for '101 (POS 30%). Co also has $255M cash/cash eq. w/ runway to '27."
0 · Reply
stayput
stayput Jul. 1 at 4:56 PM
$JBIO Still looking for $12
0 · Reply
MONSTER_MOVER_STOCKS
MONSTER_MOVER_STOCKS Jul. 1 at 2:19 AM
$JBIO It's coming...
0 · Reply
Aristoteli
Aristoteli Jun. 23 at 12:59 PM
$JBIO
0 · Reply
dojidad
dojidad Jun. 22 at 6:41 PM
$JBIO Increase in volume and increase in price is bullish. I'll see what Monday looks like and do my DD, but I wouldn't take a big position under that gap (unless there is a strong catalyst). That's a heck of a gap.
0 · Reply
MONSTER_MOVER_STOCKS
MONSTER_MOVER_STOCKS Jun. 21 at 1:38 AM
$JBIO This one looks about ready for a big move up. Current price is $10.17:
0 · Reply
tgewaz1
tgewaz1 Jun. 21 at 12:53 AM
$JBIO Tell me what in the blazing hell happened to this stock over 88 dollars to this?
1 · Reply
Latest News on JBIO
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Sep 2, 2025, 7:00 AM EDT - 12 days ago

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Jade Biosciences to Participate in Upcoming Conferences

Aug 25, 2025, 7:00 AM EDT - 20 days ago

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 4 weeks ago

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jul 8, 2025, 7:00 AM EDT - 2 months ago

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

Jul 1, 2025, 7:00 AM EDT - 2 months ago

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Jun 9, 2025, 7:00 AM EDT - 3 months ago

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

Jun 2, 2025, 7:00 AM EDT - 3 months ago

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 4 months ago

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 4 months ago

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

dogDazeSummer
dogDazeSummer Sep. 9 at 2:43 PM
Only 5 new adds for RA in latest Q: $HNGE $JBIO $TNGX $WGS and a “pipeline in pill” company from Germany, forgot the name. Total holdings are 63 many making ATH today. Interesting focus on immune dermatology. Here’s how much cash he dropped into each new starter position: Might want to follow these 5 names. $15M into Hinge $9.9m into Jade $7.3m into Omada $5.4m into GeneDx $3.2k into Inflarx
1 · Reply
GrowthStrategist
GrowthStrategist Aug. 27 at 10:17 AM
$JBIO hovering near recent highs, careful of a pullback.
0 · Reply
JarvisFlow
JarvisFlow Aug. 14 at 2:03 PM
Wedbush has updated their rating for Jade Biosciences ( $JBIO ) to Outperform with a price target of 18.
0 · Reply
Quantumup
Quantumup Jul. 14 at 7:09 PM
Jefferies🏁 $JBIO Buy-$16 $VRTX $OTSKF Jefferies said in its initiation report: "We like $JBIO's long-acting anti-APRIL (JADE101) in IgAN: 1) our PK work suggests '101 can achieve Q8/12W dosing, 2) we think efficacy will be as good as povetacicept w/ pot'l upside on % clinical remission, 3) we expect tolerable safety profile w/o increased serious infections, 4) we see oppty for disease modifying tx w/ longer dosing interval in IgAN. We model $915M risk-adj. PS for '101 (POS 30%). Co also has $255M cash/cash eq. w/ runway to '27."
0 · Reply
stayput
stayput Jul. 1 at 4:56 PM
$JBIO Still looking for $12
0 · Reply
MONSTER_MOVER_STOCKS
MONSTER_MOVER_STOCKS Jul. 1 at 2:19 AM
$JBIO It's coming...
0 · Reply
Aristoteli
Aristoteli Jun. 23 at 12:59 PM
$JBIO
0 · Reply
dojidad
dojidad Jun. 22 at 6:41 PM
$JBIO Increase in volume and increase in price is bullish. I'll see what Monday looks like and do my DD, but I wouldn't take a big position under that gap (unless there is a strong catalyst). That's a heck of a gap.
0 · Reply
MONSTER_MOVER_STOCKS
MONSTER_MOVER_STOCKS Jun. 21 at 1:38 AM
$JBIO This one looks about ready for a big move up. Current price is $10.17:
0 · Reply
tgewaz1
tgewaz1 Jun. 21 at 12:53 AM
$JBIO Tell me what in the blazing hell happened to this stock over 88 dollars to this?
1 · Reply
spark_forge_31
spark_forge_31 Jun. 20 at 5:51 PM
$JBIO
0 · Reply
VolcanicTrades
VolcanicTrades Jun. 20 at 1:51 PM
$JBIO setting up nicely….
0 · Reply
ZavenTheRapper
ZavenTheRapper Jun. 19 at 4:58 PM
$JBIO this is the CEOs song lmao https://youtu.be/zHbrvswpO_Y?si=P3wUgyBRC2A_pkY3
0 · Reply
topstockalerts
topstockalerts Jun. 19 at 4:46 PM
$JBIO curling back up?💪💪🚀🚀
0 · Reply
VolcanicTrades
VolcanicTrades Jun. 18 at 4:19 PM
$JBIO boom 💥 soon imo
0 · Reply
stayput
stayput Jun. 18 at 3:26 PM
$JBIO Come on $12
0 · Reply
AlgoWisp
AlgoWisp Jun. 18 at 1:37 PM
$JBIO
1 · Reply
stayput
stayput Jun. 18 at 1:01 AM
$JBIO Pick me up at $12
0 · Reply
VolcanicTrades
VolcanicTrades Jun. 17 at 8:27 PM
$JBIO sub 500k float setting up. Recent $14 target. Could go huge running a bit more 👀📈
0 · Reply